Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.

@article{Yoon2016RamucirumabCW,
  title={Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.},
  author={Harry H. Yoon and Johanna C. Bendell and Fadi S. Braiteh and Irfan D Firdaus and Philip Agop Philip and Allen Lee Cohn and Nancy L. Lewis and Daniel M Anderson and Edward R. Arrowsmith and Jonathan D Schwartz and Ling Gao and Yanzhi Hsu and Yihuan Xu and David Ferry and Steven Robert Alberts and Zev A. Wainberg},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2016},
  volume={27 12},
  pages={2196-2203}
}
BACKGROUND We report the first randomized, Phase II trial of ramucirumab, an anti-vascular endothelial growth factor receptor-2 monoclonal antibody, as front-line therapy in patients with advanced adenocarcinoma of the esophagus or gastric/gastroesophageal junction (GEJ). PATIENTS AND METHODS Patients from the USA with advanced esophageal, gastric, or GEJ adenocarcinoma randomly received (1:1) mFOLFOX6 plus ramucirumab (8 mg/kg) or mFOLFOX6 plus placebo every 2 weeks. The primary end point… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Recent advancements in esophageal cancer treatment in Japan

Annals of gastroenterological surgery • 2018
View 1 Excerpt

Similar Papers

Loading similar papers…